BONE MARROW TRANSPLANTATION

Scope & Guideline

Elevating Standards in Hematology and Transplantation.

Introduction

Immerse yourself in the scholarly insights of BONE MARROW TRANSPLANTATION with our comprehensive guidelines detailing its aims and scope. This page is your resource for understanding the journal's thematic priorities. Stay abreast of trending topics currently drawing significant attention and explore declining topics for a full picture of evolving interests. Our selection of highly cited topics and recent high-impact papers is curated within these guidelines to enhance your research impact.
LanguageEnglish
ISSN0268-3369
PublisherSPRINGERNATURE
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 1986 to 2024
AbbreviationBONE MARROW TRANSPL / Bone Marrow Transplant.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressCAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND

Aims and Scopes

The journal 'BONE MARROW TRANSPLANTATION' focuses on the latest advancements and research findings in the field of hematopoietic stem cell transplantation (HSCT) and related cellular therapies. It encompasses a wide range of studies, from clinical trials to epidemiological analyses, aiming to improve the understanding and treatment of hematological malignancies and other disorders through transplantation.
  1. Hematopoietic Stem Cell Transplantation (HSCT):
    The journal emphasizes research on the efficacy, safety, and outcomes of HSCT for various hematological disorders, including leukemia, lymphoma, and myelodysplastic syndromes. This encompasses studies on conditioning regimens, donor selection, and post-transplant care.
  2. Graft-versus-Host Disease (GVHD):
    A significant part of the journal's focus is on the prevention, diagnosis, and treatment of GVHD, a common complication following HSCT. This includes exploring novel prophylactic strategies and therapies for managing acute and chronic GVHD.
  3. Innovative Therapies and Techniques:
    Research on novel cellular therapies such as CAR-T cell therapy, as well as advancements in immunotherapy and targeted therapies, is frequently published, reflecting the journal's commitment to integrating new treatment modalities into clinical practice.
  4. Infectious Complications and Management:
    The journal addresses the challenges of infectious complications in HSCT recipients, including the management of viral reactivations (e.g., CMV, EBV) and bacterial infections, highlighting the importance of prophylactic strategies and treatment protocols.
  5. Patient-Centered Care and Quality of Life:
    Studies examining the psychosocial aspects, quality of life, and long-term outcomes of patients undergoing HSCT are also a critical focus, emphasizing the holistic approach to patient care.
The journal reflects ongoing advancements and shifts in research focus, with several emerging themes gaining attention. These trends indicate the evolving landscape of hematopoietic stem cell transplantation and associated therapies.
  1. Post-Transplant Cyclophosphamide (PTCy):
    There is a growing body of research dedicated to the use of PTCy as a prophylactic treatment in haploidentical stem cell transplantation, highlighting its effectiveness in reducing GVHD and improving transplant outcomes.
  2. CAR-T Cell Therapy:
    The ongoing exploration of CAR-T cell therapy in various hematological malignancies, particularly in relapsed or refractory cases, is a prominent theme, showcasing its integration into transplantation protocols.
  3. Patient Engagement and Quality of Life Research:
    An increasing focus on patient-reported outcomes and quality of life in HSCT recipients signifies a shift towards more patient-centered research, emphasizing the importance of psychosocial factors in treatment success.
  4. Microbiome Research in Transplantation:
    Emerging studies investigating the role of gut microbiota in transplant outcomes and GVHD are gaining traction, reflecting a broader interest in the interplay between microbiome health and patient recovery.
  5. Use of Advanced Imaging and Biomarkers:
    The integration of advanced imaging techniques and biomarker research to predict outcomes post-transplantation is becoming more common, enhancing the ability to tailor treatments to individual patient needs.

Declining or Waning

While 'BONE MARROW TRANSPLANTATION' continues to evolve, certain themes and areas of research are witnessing a decline in prominence. This may reflect shifts in clinical priorities, emerging treatments, or changes in the scientific landscape.
  1. Traditional Conditioning Regimens:
    There is a noticeable decrease in studies focused solely on traditional myeloablative conditioning regimens as researchers increasingly explore reduced-intensity and non-myeloablative approaches, which are becoming more favored in practice.
  2. Single Donor Transplantation Studies:
    Research focusing on single donor transplantation models, particularly in less diverse donor settings, is becoming less common as the field shifts towards exploring haploidentical and mismatched donor strategies, which are gaining traction.
  3. Basic Science Studies on Stem Cell Biology:
    There seems to be a waning interest in basic science research solely focused on stem cell biology without direct clinical applications, as more research is geared towards translational studies and clinical outcomes.
  4. Longitudinal Studies with Limited Sample Sizes:
    The frequency of longitudinal studies with small sample sizes appears to be decreasing, as there is a growing emphasis on larger, multicenter studies that offer more robust data and generalizable findings.

Similar Journals

INTERNATIONAL JOURNAL OF HEMATOLOGY

Fostering Global Insights in Blood Research
Publisher: SPRINGER JAPAN KKISSN: 0925-5710Frequency: 12 issues/year

The INTERNATIONAL JOURNAL OF HEMATOLOGY, published by SPRINGER JAPAN KK, serves as a critical platform for advancing research in the field of hematology. With a prestigious history spanning over three decades from 1991 to 2024, this journal is recognized for its impactful contributions, evidenced by its Q2 category ranking in Hematology for 2023, and its notable position at rank #71 out of 137 in the Scopus Medicine Hematology category. Researchers and professionals within the hematology community benefit from the journal's rigorous peer-reviewed articles that cover a wide range of topics, including clinical studies, basic research, and novel therapeutic strategies. Though currently non-open access, it provides essential insights and findings to an audience passionate about the latest advancements in blood disorders and treatments. Situated in Japan, the journal not only showcases high-quality research but also fosters a global exchange of knowledge in hematology, making it a significant resource for scholars, practitioners, and students alike.

Iraqi Journal of Hematology

Innovative Insights for Blood Health
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 2072-8069Frequency: 2 issues/year

Iraqi Journal of Hematology is a prominent peer-reviewed open-access journal dedicated to advancing the field of hematology. Published by Wolters Kluwer Medknow Publications, this journal provides a platform for researchers, professionals, and students to share cutting-edge findings and developments in various aspects of hematology, including blood diseases, diagnostics, and innovative treatments. Since its transition to open access in 2016, the journal has significantly increased its reach, allowing for wider dissemination of critical research to a global audience. With an ISSN of 2072-8069 and an E-ISSN of 2543-2702, the Iraqi Journal of Hematology strives to adhere to the highest scholarly standards and plays a vital role in the ongoing discourse in hematological research. Researchers are encouraged to contribute to this essential resource for the scientific community, contributing to the advancement of knowledge that ultimately improves patient care and treatment outcomes.

Transplant Immunology

Pioneering Research at the Intersection of Immunology and Transplantation.
Publisher: ELSEVIERISSN: 0966-3274Frequency: 6 issues/year

Transplant Immunology is a leading interdisciplinary journal published by Elsevier, dedicated to the advancing field of transplant science and immunology. With a strong reputation in the academic community, it currently holds a significant position in the Q3 quartile in both the Immunology and Allergy categories, as well as Q2 in Transplantation, reflecting its impact and relevance within these fields. Since its inception in 1993, the journal has explored a broad spectrum of topics, ranging from immunological mechanisms to clinical aspects of transplantation, serving as a vital resource for researchers, healthcare professionals, and students alike. Although it is not an open-access journal, it offers critical insights and innovative research findings that bridge theoretical knowledge and practical application, thereby enhancing our understanding of transplant immunology. As the field continues to evolve, Transplant Immunology remains committed to publishing high-quality studies that advance the dialogue between immunology and transplantation, fostering collaboration and discovery.

BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Leading the Way in Clinical Hematology Research
Publisher: ELSEVIER SCI LTDISSN: 1521-6926Frequency: 4 issues/year

BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY is a leading academic journal published by ELSEVIER SCI LTD, dedicated to advancing knowledge in the field of clinical hematology. Since its inception in 1999, the journal has provided a platform for high-quality research, offering insights that bridge the gap between clinical practice and breakthrough scientific discoveries. With its significant standing, the journal has garnered a Q2 ranking in both Clinical Biochemistry and Oncology as of 2023, indicating its influence and authority within these domains. Although it does not operate under an open-access model, BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY remains essential for researchers, healthcare professionals, and students looking to stay informed about the latest developments in hematological science. The journal's rigorous peer-review process and commitment to publishing innovative studies make it a cornerstone resource for anyone invested in clinical hematology and related fields.

Journal of Hematology

Innovating Insights into Blood Disorders
Publisher: ELMER PRESS INCISSN: 1927-1212Frequency: 4 issues/year

The Journal of Hematology, published by ELMER PRESS INC, serves as a pivotal platform for disseminating cutting-edge research in the field of hematology. With an ISSN of 1927-1212 and an E-ISSN of 1927-1220, this journal is committed to advancing scientific knowledge and clinical practice through high-quality peer-reviewed articles encompassing all aspects of blood disorders, from basic science to health policy implications. While the journal currently operates under a traditional access model, it nonetheless prioritizes the rapid publication of significant findings, ensuring that researchers, clinicians, and students have timely access to the latest advancements in hematological research. Positioned to bridge gaps in knowledge and foster collaboration among scholars worldwide, the Journal of Hematology is an essential resource for anyone invested in this vital area of medicine.

JOURNAL OF CLINICAL IMMUNOLOGY

Innovating Therapeutic Strategies for Immune Health
Publisher: SPRINGER/PLENUM PUBLISHERSISSN: 0271-9142Frequency: 8 issues/year

JOURNAL OF CLINICAL IMMUNOLOGY, published by SPRINGER/PLENUM PUBLISHERS, is a leading journal in the field of immunology, with an impressive standing as reflected in its Q1 ranking in both Immunology and Immunology and Allergy for 2023. With a history of publication dating back to 1981 and an E-ISSN of 1573-2592, this journal aims to disseminate cutting-edge research on diagnostic methods, therapeutic strategies, and understanding the mechanisms underlying immune responses. Its significant impact is underscored by its Scopus rankings, where it is placed in the top 15% of journals covering immunology and microbiology. The journal does not currently operate under an Open Access model, yet offers a robust platform for sharing essential findings that contribute to advancements in clinical immunology. As a resource for researchers, professionals, and students, the JOURNAL OF CLINICAL IMMUNOLOGY is pivotal in fostering dialogue and disseminating knowledge that enhances our understanding of immune-related diseases.

Turkish Journal of Hematology

Unveiling the latest breakthroughs in blood health and treatment.
Publisher: GALENOS PUBL HOUSEISSN: 1300-7777Frequency: 4 issues/year

Turkish Journal of Hematology is an esteemed publication dedicated to advancing the field of hematology, producing influential research since its inception in 1999 under the auspices of GALENOS PUBL HOUSE. With an Open Access model, it facilitates widespread dissemination of knowledge, allowing researchers, clinicians, and students to stay abreast of the latest developments in blood disorders and treatments. With an ISSN of 1300-7777 and an E-ISSN of 1308-5263, the journal holds a commendable position in the academic community, evidenced by its 2023 Q3 ranking within the hematology category and its standing at #80 out of 137 in the Scopus database, placing it in the 41st percentile. Covering a wide scope of topics within hematology, this journal serves as a critical resource for disseminating innovative research and clinical practices pertinent to the ongoing challenges faced in this vital area of medicine. With its continuous publication until 2024, Turkish Journal of Hematology remains a beacon for enhancing the understanding and treatment of hematological conditions within the Turkish and global medical communities.

Therapeutic Advances in Hematology

Elevating therapeutic practices in hematology.
Publisher: SAGE PUBLICATIONS LTDISSN: 2040-6207Frequency: 1 issue/year

Therapeutic Advances in Hematology is a prestigious, peer-reviewed journal dedicated to advancing the field of hematology through innovative research and clinical studies. Published by SAGE Publications Ltd, this journal has become a vital resource for hematology professionals and researchers since its inception in 2010. With its impactful Q1 ranking in Hematology and a Scopus rank of 62 out of 137, it firmly establishes itself as a leader in disseminating significant findings and therapeutic approaches. The journal has been committed to open access since 2019, ensuring that its cutting-edge research is readily available to the global scientific community. Covering a broad scope of topics within hematology, Therapeutic Advances in Hematology is an essential platform for those seeking to enhance their understanding and implementation of therapeutic practices in hematological conditions. The journal embraces submissions from both clinical and laboratory perspectives, fostering collaboration and dialogue among researchers, clinicians, and students alike.

ACTA HAEMATOLOGICA

Elevating Research in Hematology and Beyond
Publisher: KARGERISSN: 0001-5792Frequency: 6 issues/year

ACTA HAEMATOLOGICA, published by KARGER, is a prestigious journal established in 1948, dedicated to the field of hematology and related medical sciences. With an ISSN of 0001-5792 and an E-ISSN of 1421-9662, this journal stands out with a Q2 ranking in both Hematology and Miscellaneous Medicine categories as of 2023. Researchers and professionals can benefit from its high-quality peer-reviewed articles, contributing to a more profound understanding and advancement of hematological practices. Although it does not offer open access options, ACTA HAEMATOLOGICA remains an essential resource for researchers in Switzerland and worldwide, providing critical insights and fostering discourse among academic and clinical communities. The journal's address is located in the heart of Basel, Switzerland, ensuring its robust connection to European medical research networks. With a firm commitment to excellence, this publication plays a vital role in disseminating knowledge, guiding future innovations in the field.

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY

Bridging research and practice in pediatric hematology and oncology.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 1077-4114Frequency: 8 issues/year

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, published by Lippincott Williams & Wilkins, serves as a vital platform for the dissemination of cutting-edge research and insights in the fields of pediatric hematology and oncology. Since its inception in 1979, the journal has maintained a commitment to advancing knowledge through peer-reviewed articles that contribute to the understanding and treatment of blood disorders and cancers in children. With an impact factor reflective of its academic contributions, the journal is positioned in the Q3 quartile across key medical categories — Hematology, Oncology, and Pediatrics, Perinatology and Child Health — indicating its relevance and influence in the field. While it does not currently offer open access options, the journal remains a crucial resource for researchers, clinicians, and students dedicated to improving pediatric care and outcomes. Researchers are encouraged to contribute to this esteemed journal as it seeks to bridge the gap between clinical practice and research, fostering innovation and improved quality of life for young patients affected by hematologic and oncologic conditions.